This Is Novavax's Biggest Weakness Right Now -- and Here's How the Company May Overcome It

This Is Novavax's Biggest Weakness Right Now -- and Here's How the Company May Overcome It

Novavax (NASDAQ: NVAX) investors have been eagerly awaiting one thing -- for the company to request authorization to sell its coronavirus vaccine candidate. Earlier this year, Novavax indicated that would happen in the second quarter. During the first-quarter earnings report this week, Novavax said it needed more time.